膜杰作
Star Staining
抗体来源（Source）
Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) is a mouse monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which provides higher batch consistency and long term security of supply.
应用（Application）
Flow Cytometry (Detection the expression of CD19 on Human cells).
克隆号（Clone）
FMC63
种属（Species）
Mouse
亚型（Isotype）
Mouse IgG2a | Mouse kappa
特异性（Specificity）
This product is a specific antibody specifically reacts with CD19 protein.
种属反应性（Reactivity）
Human
免疫原（Immunogen）
Human prolymphocytic leukaemia cell line JVM3.
偶联（Conjugate）
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
推荐稀释比（Recommended Dilution）
1:50
制剂（Formulation）
Supplied as 0.2 μm filtered solution in PBS, 0.03% Proclin 300, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
存储（Storage）
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 12 months under sterile conditions.
活性（Bioactivity）-FACS
Flow cytometric analysis of Human peripheral blood lymphocytes staining with FITC-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) (Cat. No. CD9-FM7A1) at 1:50 dilution (2 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL), compared with isotype control antibody. FITC signal was used to evaluate the binding activity (QC tested).
Protocol
Flow cytometric analysis of Human peripheral blood lymphocytes staining with PE anti-human CD3 antibody and FITC-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) (Cat. No. CD9-FM7A1) at 1:50 dilution (2 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL). FITC signal was used to evaluate the binding activity (QC tested).
Protocol
背景（Background）
FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.
